Moreover, their immunosuppressive properties and low immunogenicity contribute to a reduced or weakened immune response elicited by the implantation of allogeneic JCB-MSCs compared with other cell types. JCB-MSCs products are less invasive than adipose tissue extraction and bone marrow aspiration, resulting in less time-consuming procedures and, more importantly, less pain. JCB-MSCs does not use any material obtained directly from the embryo or fetus. JCB-MSCs has higher concentrations of peptides, hyaluronic acid, and growth factors when compared to amniotic fluid suspensions. Due to high concentrations of growth factors in the Umbilical Cord Matrix, also known as Wharton’s Jelly, it acts as an ideal anti-inflammatory and has been shown in clinical studies to prevent apoptosis. JCB-MSCs is processed from human tissue, donated following full-term, C-section deliveries, in accordance with the FDA.

Allogenic JCB-MSCs are an exciting biological therapy option because of their low immunogenicity, immunosuppressive properties, and tissue repair capabilities based on multiple evidence-based therapies. Plaxoquantine, provided by Bioquark, Inc., is a unique and novel biological complex that mimics the regulatory biochemistry of a living human egg (oocyte) immediately after fertilization. During this period, oocytes undertake an unprecedented set of tasks, including restoring cellular age, reprogramming DNA to eliminate genetic and epigenetic damage, remodeling organelles, and protecting the embryo from inflammatory, oxidative, or infectious factors. This state-of-the-art isolated protein complex can provide the perfect biological environment to enhance cellular functions.